Gestational complications resulting from thrombophilia account for about 75% of the causes of neonatal morbidity and mortality.

Thrombophilia is potentiated in pregnancy and puerperium due to the procoagulant characteristics of these conditions.  They can be classified as: acquired and hereditary and affect approximately 15% of the general population.

Gestational complications caused by thrombophilia can be described as placental thrombosis, severe forms of gestational hypertension, premature placental detachment, intrauterine fetal growth restriction, which may progress to fetal death. These complications represent about 75% of the causes of neonatal morbidity and mortality.

The new THROMBOINCODE Genetic evaluation reproductive health, offered by SYNLAB, assesses the risk of venous thromboembolism during pregnancy and the puerperium by analyzing 12 variants in 7 genes associated with thrombophilia. The result is obtained through a mathematical algorithm that makes it possible to assess the patient’s risk in three ways: the patient’s risk of having thrombophilia associated with the current clinical condition (variable factors such as weight, smoking, habits and lifestyle); patient risk compared to the risk of heterozygosity for Factor V Leiden, with the same clinical profile, and the risk with the same clinical profile considering the genetic variants found. Enabling a complete analysis of the genetic implications for the risk of thrombophilia and, in turn, of recurrent pregnancy loss.

About the SYNLAB Group

The SYNLAB Group is a leader in providing medical diagnostic services in Europe, providing a full range of clinical laboratory analysis services to patients, healthcare professionals, clinics and the pharmaceutical industry. Resulting from the Labco and SYNLAB merger, the new SYNLAB Group is the undisputed European leader in medical laboratory services.